Our partner in Algeria
Algeria is one of the beneficiaries of the EU-funded EU4Monitoring Drugs II (EU4MD) project, which has been developed by the EMCDDA as part of its ongoing commitment to strengthening cooperation and sharing expertise with countries in the European Neighbourhood Policy (ENP) area.
News
Events
Publications
Publications related to this partner
This timeline allows you to explore a timeline highlighting some of the EU4Monitoring Drugs (EU4MD) project's achievements. As part of its ongoing commitment to strengthening cooperation and sharing expertise, EMCDDA developed the EU4Monitoring Drugs (EU4MD) project, funded by the European Union.
This report presents an analysis of the drug markets in the European Neighbourhood Policy-South region covering Algeria, Egypt, Israel, Jordan, Lebanon, Libya, Morocco, Palestine (*), Syria and Tunisia.
Between March and May 2021, the EU4Monitoring Drugs (EU4MD) project supported the mapping of national prevention systems in European Neighbourhood Policy (ENP) area countries.
Since the beginning of 2020, the world has been experiencing an unprecedented public health emergency caused by the coronavirus disease (COVID-19) pandemic, which has led to the progressive introduction of social distancing and other control measures by national governments.
Follow the timeline and take a walk through some of the key moments in the EMCDDA's 25 years of international cooperation.
The EU drugs agency in Lisbon, as part of its ongoing commitment to strengthening cooperation and sharing expertise, has developed the EU4Monitoring Drugs (EU4MD) project.
Contact information
Algerian National Office against Drugs and Drug Addiction (Office National de la Lutte Contre la Drogue et la Toxicomanie)